Pulmonary hypertension

Mocumbi, Ana; Humbert, Marc; Saxena, Anita; Jing, Zhi-Cheng; Sliwa, Karen; Thienemann, Friedrich; Archer, Stephen L.; Stewart, Simon

doi:10.1038/s41572-023-00486-7

Cited by 61 publications

(3 citation statements)

References 223 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Older patients over the age of 65 have an estimated PH prevalence of 10%, and those with comorbidities such as aortic stenosis or heart failure (HF) with preserved ejection fraction (HFpEF) have a higher prevalence of PH ranging from around 30-90% depending upon how it is evaluated [14][15][16][17]. Despite scanty evidence, studies do suggest that those with residence in economically developing nations, poor healthcare access, low annual income, higher risk of diseases such as tuberculosis and human immunodeficiency virus (HIV) infection, and low health literacy have a higher prevalence of PH and worse FC and are less likely to receive adequate diagnosis and treatment [18][19][20][21][22][23]. Through mechanisms such as inflammation and vascular injury, COVID-19 cohorts are associated with higher prevalence of PH, in part due to the high prevalence of pre-existing PH with lung and heart comorbidities in COVID-19 patients [24][25][26].…”

Section: Demographics and Costmentioning

confidence: 99%

See 1 more Smart Citation

Pulmonary Hypertension: Pharmacological and Non-Pharmacological Therapies

Tsai,

Malik,

Tjen-A-Looi

2024

Preprint

View full text Add to dashboard Cite

Pulmonary hypertension (PH) is a severe and chronic disease characterized by increased pulmonary vascular resistance and remodeling often precipitating right-sided heart dysfunction and death. Although the condition is progressive and incurable, current therapies for the disease focus on multiple different drugs and general supportive therapies to manage symptoms and prolong survival, ranging from medications more specific to pulmonary arterial hypertension (PAH) to exercise training. Moreover, there are multiple studies exploring novel experimental drugs and therapies including unique neurostimulation, to help better manage the disease. Here we provide a narrative review focusing on current PH treatments that target multiple underlying biochemical mechanisms, including but not limited to imbalances in vasoconstrictor-vasodilator and autonomic nervous system function, inflammation, and bone morphogenic protein (BMP) signaling. We also focus on the potential of novel therapies for managing PH, focusing on multiple types of neu-rostimulation including acupuncture. Lastly, we also touch upon the disease’s different subgroups, clinical presentations and prognosis, diagnostics, demographics, and cost.

show abstract

Section: Demographics and Costmentioning

confidence: 99%

“…However, regardless of the specific group, current trends indicate that the prevalence of PH is rising. Consequently, it is necessary to understand and tackle certain risk factors associated with PH, such as disease prevention and healthcare equity programs, along with finding novel therapies [1,18].…”

Section: Demographics and Costmentioning

confidence: 99%

Pulmonary Hypertension: Pharmacological and Non-Pharmacological Therapies

Tsai,

Malik,

Tjen-A-Looi

2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Additionally, PH frequently complicates the clinical course of patients with lung diseases and/or hypoxemia, such as chronic obstructive pulmonary disease and interstitial lung disease (group 3 PH). This comorbidity exacerbates the already elevated morbidity and mortality rates associated with these conditions ( 4 ). Despite intense research endeavors and Food and Drug Administration (FDA)-approved drugs that mainly target pulmonary vasoconstriction ( 2 , 3 , 5 ), the prognosis of patients with group 1 and group 3 PH remains poor, emphasizing the urgent need for a better understanding of the molecular mechanisms leading to vascular remodeling.…”

mentioning

confidence: 99%

A HIF-2α-dependent KMT2E-AS1/KMT2E axis orchestrates endothelial epigenetic and metabolic dysfunction in pulmonary hypertension

Lemay,

Provencher,

Bonnet

et al. 2024

Ann Transl Med

View full text Add to dashboard Cite

A High‐Stability Pressure‐Sensitive Implantable Memristor for Pulmonary Hypertension Monitoring

Cao,

Liu,

Sun

et al. 2024

Advanced Materials

View full text Add to dashboard Cite

Pulmonary hypertension (PH) significantly affects the quality of life and lifespan of humans and has promoted the development of flexible implantable electronic devices for PH diagnosis and prevention. Traditional implantable devices based on the von Neumann architecture face insurmountable challenges in processing large amounts of biological data due to computational bottlenecks. Memristors, with integrated in‐memory sensing and computing capabilities, can effectively eliminate computational bottlenecks and become one of the most promising products in implantable devices for health monitoring. Here, a memristor with the Ag/MnO2/BaTiO3/FTO structure is implemented and implanted into Sprague‒Dawley (SD) rats. With polydimethylsiloxane (PDMS) packaging, the device can be continuously worked in vivo for up to four weeks, demonstrating excellent stability and biocompatibility. Furthermore, a memristive sensor array is designed for pulmonary artery blood pressure monitoring based on the pressure‐responsive characteristics of the as‐prepared memristive device. The front‐end memristive sensor array can collect and feedback pressure signal, while noise reduction is achieved through memristive logic circuits, and ultimately the memristor neural network processes and classifies the information. Therefore, this work demonstrates the potential of implantable memristors for pulmonary artery pressure monitoring and provides new inspiration for the design of efficient, real‐time, and reliable implantable pressure monitoring devices in medical health monitoring.

show abstract

Pulmonary hypertension

Cited by 61 publications

References 223 publications

Pulmonary Hypertension: Pharmacological and Non-Pharmacological Therapies

Pulmonary Hypertension: Pharmacological and Non-Pharmacological Therapies

A HIF-2α-dependent KMT2E-AS1/KMT2E axis orchestrates endothelial epigenetic and metabolic dysfunction in pulmonary hypertension

A High‐Stability Pressure‐Sensitive Implantable Memristor for Pulmonary Hypertension Monitoring

Contact Info

Product

Resources

About